Literature DB >> 17879364

New therapies for hepatitis C.

Apurva A Modi, Jay H Hoofnagle.   

Abstract

Mesh:

Substances:

Year:  2007        PMID: 17879364     DOI: 10.1002/hep.21892

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms.

Authors:  Kara L Norman; Peter Sarnow
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 2.  Hepatitis C protease and polymerase inhibitors in development.

Authors:  Gustine Liu-Young; Michael J Kozal
Journal:  AIDS Patient Care STDS       Date:  2008-06       Impact factor: 5.078

Review 3.  Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

Authors:  Brian L Pearlman
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

4.  Targeting HCV entry for development of therapeutics.

Authors:  Flossie Wong-Staal; Andrew J Syder; Jeffrey F McKelvy
Journal:  Viruses       Date:  2010-08-18       Impact factor: 5.818

5.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.